By Fineline Cube 
JD Healthcare (HKG: 6618), a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), released its Q1 2025 financial report. Total revenues increased by 25.5% year-on-year (YOY) to RMB 16.645 billion (USD 2.3 billion). Operating profits soared by 119.8% to RMB 1.071 billion (USD 148.4 million).
New Drug Launches
During the quarter, JD Healthcare introduced several innovative drugs online, including Pfizer’s Talzenna (talazoparib), Esteve’s Lysodren (mitotane), and Innogen’s Yinuoqing (efsubaglutide alfa). These additions aimed to provide patients with more medication options.
Partnership Expansion
The company strengthened collaborations with leading health product companies such as BY-HEALTH, YanPlace, and LifeStyles. The partnerships focused on product innovation, digital supply chain integration, and precision marketing.
Medical AI Advancements
JD Healthcare made significant strides in medical AI. The company launched the “AI Beijing Medical” product system, enabling online multi-scenario applications. This system offers intelligent diagnostic support and research assistance for doctors, as well as personalized medical and health services for users through AI-driven services from doctors, pharmacists, and nutritionists. The company’s medical large model became open-source, marking it as the first fully open-source vertical model in China’s medical industry. Notably, over 80% of doctors at the JD Healthcare Internet Hospital utilized AI services, with AI nutritionists achieving a 91% satisfaction rate.-Fineline Info & Tech